October 16, 2017 Article in Bioprocess International Vol 15, Issue 8, Featured Report, September 2017
Stefan R. Schmidt
Some proteins can be engineered from fusion genes, developed by joining two different genes. Such proteins can be used in therapeutic applications that have extended half-lives, improved efficacies, reduced immunogenicity or toxicity, and enhanced pharmacokinectics. Schmidt discusses both N-linked and O-linked glycosylation to enhance circulation times and improve efficacy of therapeutic proteins. Both upstream and downstream processing approaches for controlling glycosylation are addressed.
You will find our article here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication